TP
RVMD icon

Thunderbird Partners’s Revolution Medicines RVMD Stock Holding History

Thunderbird Partners’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-344,324
Closed -$6.71M – 14
2022
Q2 		$6.71M Buy
+344,324
New +$6.7M 1.6% 10

Other funds holding RVMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Thunderbird Partners's RVMD Position: Q3 2022 in Review

Thunderbird Partners sold out of Revolution Medicines (RVMD) in Q3 2022, closing a stake of 344,324 shares — an estimated $6.71M sold.

Thunderbird Partners first reported a position in RVMD in Q2 2022 and held it in 1 quarter. The position peaked at $6.71M in Q2 2022. 142 funds tracked by Wall St. Rank hold RVMD as of Q3 2022.

  • Thunderbird Partners reported no remaining Revolution Medicines position as of Q3 2022 after selling out during the quarter.
  • Thunderbird Partners sold 344,324 Revolution Medicines shares in Q3 2022, an estimated $6.71M.
  • Thunderbird Partners first reported a position in Revolution Medicines in Q2 2022 and held it in 1 quarter.
  • Thunderbird Partners's Revolution Medicines position peaked at $6.71M in Q2 2022.
  • 142 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2022.

Based on Thunderbird Partners's 13F filing for Q3 2022, filed 14 Nov 2022.